Cagrilintide is a long-acting analog of the naturally occurring hormone amylin. Amylin is co-secreted with insulin from pancreatic beta cells and plays a role in glucose homeostasis and appetite regulation.
The compound has been studied as a once-weekly injectable for weight management. Its mechanism involves slowing gastric emptying, promoting satiety, and reducing food intake through central nervous system pathways.
Research interest in cagrilintide increased significantly when combination studies with semaglutide (a GLP-1 agonist) showed enhanced weight reduction compared to either compound alone. The combination targets two different hormonal pathways simultaneously.
Cagrilintide is part of a broader trend in metabolic research toward multi-receptor targeting. While tirzepatide targets GIP and GLP-1, and retatrutide targets GIP, GLP-1, and glucagon, cagrilintide adds the amylin pathway as another axis.
The compound is available for research purposes as a lyophilized powder. All weight management claims are based on clinical trial data and do not constitute medical advice.
Disclaimer: This article is for educational purposes only. All peptides are sold for laboratory research use only. Not for human consumption.